MCM
CLDX icon

Manchester Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Manchester Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-136
Closed -$1K – 569
2019
Q1 		$1K Buy
+136
New +$715 ﹤0.01% 637

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manchester Capital Management's CLDX Position: Q2 2019 in Review

Manchester Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2019, closing a stake of 136 shares — an estimated $1K sold.

Manchester Capital Management first reported a position in CLDX in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 51 funds tracked by Wall St. Rank hold CLDX as of Q2 2019.

  • Manchester Capital Management reported no remaining Celldex Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Manchester Capital Management sold 136 Celldex Therapeutics shares in Q2 2019, an estimated $1K.
  • Manchester Capital Management first reported a position in Celldex Therapeutics in Q1 2019 and held it in 1 quarter.
  • Manchester Capital Management's Celldex Therapeutics position peaked at $1K in Q1 2019.
  • 51 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2019.

Based on Manchester Capital Management's 13F filing for Q2 2019, filed 5 Aug 2019.